Miss Elizabeth Thomson

Senior Project Manager (Robertson Centre for Biostatistics)

telephone: 01413304744
email: Elizabeth.Thomson@glasgow.ac.uk

Clarice Pears Building, Level 5, 90 Byres Road, Glasgow, G12 8TB

Import to contacts

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2022 | 2015

Number of items: 8.

2025

Ahmed, F.Z. et al. (2025) Effects of ferric derisomaltose in heart failure with iron deficiency according to renal function in the IRONMAN randomised controlled trial. American Journal of Nephrology, (Accepted for Publication)

Taylor, R. et al. (2025) Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial – REACH-HFpEF trial. BMJ Open, 15(5), e094254. (doi: 10.1136/bmjopen-2024-094254) (PMID:40436450) (PMCID:PMC12121609)

Sze, S. et al. (2025) Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: Insights from the IRONMAN trial. Heart, (doi: 10.1136/heartjnl-2024-324908) (PMID:39938943) (Early Online Publication)

2024

Cleland, J. et al. (2024) Adjudication of hospitalizations and deaths in the IRONMAN Trial of intravenous iron for heart failure. Journal of the American College of Cardiology, 84(18), pp. 1704-1717. (doi: 10.1016/j.jacc.2024.08.052) (PMID:39443013) (PMCID:PMC11496827)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

2015

Mccowan, Colin ORCID: https://orcid.org/0000-0002-9466-833X, Thomson, Elizabeth, Szmigielski, Cezary A., Kalra, Dipak, Sullivan, Frank M., Prokosch, Hans-Ulrich, Dugas, Martin and Ford, Ian ORCID: https://orcid.org/0000-0001-5927-1823 (2015) Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR. BioMed Research International, 2015, 707891. (doi: 10.1155/2015/707891) (PMID:26539523) (PMCID:PMC4619877)

This list was generated on Fri Jul 11 20:37:24 2025 BST.

Jump to: Articles

Number of items: 8.

Articles

Ahmed, F.Z. et al. (2025) Effects of ferric derisomaltose in heart failure with iron deficiency according to renal function in the IRONMAN randomised controlled trial. American Journal of Nephrology, (Accepted for Publication)

Taylor, R. et al. (2025) Clinical effectiveness and cost-effectiveness of the rehabilitation enablement in chronic heart failure facilitated self-care rehabilitation intervention for people with heart failure with preserved ejection fraction and their caregivers: rationale and protocol for a multicentre randomised controlled trial – REACH-HFpEF trial. BMJ Open, 15(5), e094254. (doi: 10.1136/bmjopen-2024-094254) (PMID:40436450) (PMCID:PMC12121609)

Sze, S. et al. (2025) Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: Insights from the IRONMAN trial. Heart, (doi: 10.1136/heartjnl-2024-324908) (PMID:39938943) (Early Online Publication)

Cleland, J. et al. (2024) Adjudication of hospitalizations and deaths in the IRONMAN Trial of intravenous iron for heart failure. Journal of the American College of Cardiology, 84(18), pp. 1704-1717. (doi: 10.1016/j.jacc.2024.08.052) (PMID:39443013) (PMCID:PMC11496827)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Mccowan, Colin ORCID: https://orcid.org/0000-0002-9466-833X, Thomson, Elizabeth, Szmigielski, Cezary A., Kalra, Dipak, Sullivan, Frank M., Prokosch, Hans-Ulrich, Dugas, Martin and Ford, Ian ORCID: https://orcid.org/0000-0001-5927-1823 (2015) Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR. BioMed Research International, 2015, 707891. (doi: 10.1155/2015/707891) (PMID:26539523) (PMCID:PMC4619877)

This list was generated on Fri Jul 11 20:37:24 2025 BST.